Email updates

Keep up to date with the latest news and content from Lipids in Health and Disease and BioMed Central.

Open Access Research

Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status

Agnieszka Makówka, Przemysław Dryja, Grażyna Chwatko, Edward Bald and Michał Nowicki*

Lipids in Health and Disease 2012, 11:47  doi:10.1186/1476-511X-11-47

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email info@biomedcentral.com, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

Renal Dosing

Jeffrey Minniti   (2013-10-21 21:04)  Minniti

In the US, fenofibrate is contraindicated in severe renal failure (including those on chronic dialysis). It has significant renal excretion, and is not removed by hemodialysis. Those with negligible creatinine clearances would be at risk for cumulative toxicity. Neuromyopathies (including rhabdomyolysis) have been documented in this patient population. Co-administered drugs such as colchicine can potentiate this effect.

Competing interests

None

top

Post a comment